ID
Clinical reference
HIV / AIDS
HIV infection destroys CD4+ T cells. AIDS: CD4 <200 or AIDS-defining illness. ART (antiretroviral therapy) achieves viral suppression. U=U: Undetectable = Untransmittable. PrEP prevents HIV acquisition.
HIV
AIDS
HIV/AIDS
human immunodeficiency virus
Latest evidence
Latest evidence
No evidence articles returned for this search yet.
Core official overview
What this condition is
What are HIV and AIDS?HIV stands for human immunodeficiency virus. It harms your immune system by destroying a type of white blood cell that helps your body fight infection.AIDS is the final stage of infection with HIV. It happens when the body's immune system is badly damaged because of the virus. Not everyone with HIV develops AIDS.Are there treatments for HIV?There is no cure for HIV, but there are many medicines…
Open official source →
Condition family & coding
Terms and documentation support
Condition matches & synonyms
Terms
Related diagnostic names, synonyms, and documentation wording that may appear in clinical references and charting.
ICD-10 quick links
Codes
For study support, terminology recognition, and documentation language.
Common tests
Tests performed
Common medications
Recognize the drug and the class
Related nursing diagnoses
NANDA diagnoses & care plans
Use these direct links to open nursing diagnoses and care-plan support related to HIV / AIDS.
Recruiting clinical trials
Additional official research
RECRUITING
NA
NCT05044962
The study investigators are conducting foundational pharmacokinetic (PK) and qualitative studies, among 15-24 years old (inclusive) adolescent girls and young women living with HIV (AGYWLHIV) already on oral antiretroviral therapy (ART) an…
RECRUITING
PHASE3
NCT06694805
This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also cons…
RECRUITING
N/A
NCT06424964
This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes. Primary outcome • Evaluate patient perception of, and satisfaction with, long…
RECRUITING
PHASE1
NCT05418868
This is an open-label, dose-escalation study to investigate the safety, tolerability and pharmacokinetics (PK) of single subcutaneous (SC) administration of long acting (LA) Cabotegravir (CAB) 200 milligrams per milliliter (mg/mL) with Rec…
Official education links
Plain-language study support
Useful for plain-language reinforcement and quick review.